(1995): Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, Neurology 45) [7], Seite 1277-85..

(2001): PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS, Neurology 56) [12], Seite 1628-36..

Ashkenazi, A. (2002): Targeting death and decoy receptors of the tumour-necrosis factor superfamily, Nat Rev Cancer 2) [6], Seite 420-30.

Ashkenazi, A.; Pai, R. C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; McMurtrey, A. E.; Hebert, A.; DeForge, L.; Koumenis, I. L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z. und Schwall, R. H. (1999): Safety and antitumor activity of recombinant soluble Apo2 ligand, J Clin Invest 104) [2], Seite 155-62..

Ault, K.A. und Mitchell, J.G. (1992): Analysis of platelets., Laerum, O.D. und Bjerknes, R., Flow cytometry in hematology., Seite 153-163, Academic Press, London - San Diego - New York.

Balomenos, D. und Martinez, A. C. (2000): Cell-cycle regulation in immunity, tolerance and autoimmunity, Immunol Today 21) [11], Seite 551-5.

Bechmann, I.; Mor, G.; Nilsen, J.; Eliza, M.; Nitsch, R. und Naftolin, F. (1999): FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier, Glia 27) [1], Seite 62-74.

Bechmann, I.; Steiner, B.; Gimsa, U.; Mor, G.; Wolf, S.; Beyer, M.; Nitsch, R. und Zipp, F. (2002): Astrocyte-induced T cell elimination is CD95 ligand dependent, J Neuroimmunol 132) [1-2], Seite 60-5.

Bijl, M.; van Lopik, T.; Limburg, P. C.; Spronk, P. E.; Jaegers, S. M.; Aarden, L. A.; Smeenk, R. J. und Kallenberg, G. G. (1998): Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?, J Autoimmun 11) [5], Seite 457-63.

Birk, K.; Ford, C.; Smeltzer, S.; Ryan, D.; Miller, R. und Rudick, R. A. (1990): The clinical course of multiple sclerosis during pregnancy and the puerperium, Arch Neurol 47) [7], Seite 738-42.

Birk, K.; Smeltzer, S. C. und Rudick, R. (1988): Pregnancy and multiple sclerosis, Semin Neurol 8) [3], Seite 205-13.

Bodmer, J. L.; Holler, N.; Reynard, S.; Vinciguerra, P.; Schneider, P.; Juo, P.; Blenis, J. und Tschopp, J. (2000): TRAIL receptor-2 signals apoptosis through FADD and caspase-8, Nat Cell Biol 2) [4], Seite 241-3. taf/DynaPage.taf?file=/ncb/v2/n4/full/ncb0400_241.html taf/DynaPage.taf?file=/ncb/v2/n4/abs/ncb0400_241.html.

Borner, C. (2003): The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions, Mol Immunol 39) [11], Seite 615-47.

Boylan, M. T.; Crockard, A. D.; McDonnell, G. V.; McMillan, S. A. und Hawkins, S. A. (2001): Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis, Immunol Lett 78) [3], Seite 183-7.

Cascino, I.; Fiucci, G.; Papoff, G. und Ruberti, G. (1995): Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing, J Immunol 154) [6], Seite 2706-13.

Chan, F. K.; Chun, H. J.; Zheng, L.; Siegel, R. M.; Bui, K. L. und Lenardo, M. J. (2000): A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling, Science 288) [5475], Seite 2351-4.

Cheng, J.; Zhou, T.; Liu, C.; Shapiro, J. P.; Brauer, M. J.; Kiefer, M. C.; Barr, P. J. und Mountz, J. D. (1994): Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule, Science 263) [5154], Seite 1759-62.

Ciusani, E.; Frigerio, S.; Gelati, M.; Corsini, E.; Dufour, A.; Nespolo, A.; La Mantia, L.; Milanese, C.; Massa, G. und Salmaggi, A. (1998): Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients, J Neuroimmunol 82) [1], Seite 5-12.

Compston, A. und Sadovnick, A. D. (1992): Epidemiology and genetics of multiple sclerosis, Curr Opin Neurol Neurosurg 5) [2], Seite 175-81.

Crawford, M. P.; Yan, S. X.; Ortega, S. B.; Mehta, R. S.; Hewitt, R. E.; Price, D. A.; Stastny, P.; Douek, D. C.; Koup, R. A.; Racke, M. K. und Karandikar, N. J. (2004): High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay, Blood 103) [11], Seite 4222-31.

D'Souza, S. D.; Bonetti, B.; Balasingam, V.; Cashman, N. R.; Barker, P. A.; Troutt, A. B.; Raine, C. S. und Antel, J. P. (1996): Multiple sclerosis: Fas signaling in oligodendrocyte cell death, J Exp Med 184) [6], Seite 2361-70.

Dorr, J.; Bechmann, I.; Waiczies, S.; Aktas, O.; Walczak, H.; Krammer, P. H.; Nitsch, R. und Zipp, F. (2002): Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain, J Neurosci 22) [4], Seite RC209.

Dowling, P.; Husar, W.; Menonna, J.; Donnenfeld, H.; Cook, S. und Sidhu, M. (1997): Cell death and birth in multiple sclerosis brain, J Neurol Sci 149) [1], Seite 1-11.

Dudley, D. J.; Chen, C. L.; Mitchell, M. D.; Daynes, R. A. und Araneo, B. A. (1993): Adaptive immune responses during murine pregnancy: pregnancy-induced regulation of lymphokine production by activated T lymphocytes, Am J Obstet Gynecol 168) [4], Seite 1155-63.

Eckhardt, R. (1991): Durchflußzytometrie, eine schnelle und einfache Methode zur Analyse großer Zellzahlen., Lab Med 15), Seite 563-569.

Ehrlich, S.; Noam, G. G.; Lyoo, I. K.; Kwon, B. J.; Clark, M. A. und Renshaw, P. F. (2003): Subanalysis of the location of white matter hyperintensities and their association with suicidality in children and youth, Ann N Y Acad Sci 1008), Seite 265-8.

Ehrlich, S.; Noam, G. G.; Lyoo, I. K.; Kwon, B. J.; Clark, M. A. und Renshaw, P. F. (2004): White matter hyperintensities and their associations with suicidality in psychiatrically hospitalized children and adolescents, J Am Acad Child Adolesc Psychiatry 43) [6], Seite 770-6.

Emery, J. G.; McDonnell, P.; Burke, M. B.; Deen, K. C.; Lyn, S.; Silverman, C.; Dul, E.; Appelbaum, E. R.; Eichman, C.; DiPrinzio, R.; Dodds, R. A.; James, I. E.; Rosenberg, M.; Lee, J. C. und Young, P. R. (1998): Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, J Biol Chem 273) [23], Seite 14363-7..

Erdfelder, E.; Faul, F. und Buchner, A. (1996): G*Power: A general power analysis program., Behavior Research Methods, Instruments, & Computers 28), Seite 1-11.

Fanger, N. A.; Maliszewski, C. R.; Schooley, K. und Griffith, T. S. (1999): Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), J Exp Med 190) [8], Seite 1155-64..

Fowlkes, B. J.; Schwartz, R. H. und Pardoll, D. M. (1988): Deletion of self-reactive thymocytes occurs at a CD4+8+ precursor stage, Nature 334) [6183], Seite 620-3.

Gelati, M.; Corsini, E.; De Rossi, M.; Masini, L.; Bernardi, G.; Massa, G.; Boiardi, A. und Salmaggi, A. (2002): Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis, Arch Neurol 59) [5], Seite 774-80.

Gniadek, P.; Aktas, O.; Wandinger, K. P.; Bellmann-Strobl, J.; Wengert, O.; Weber, A.; von Wussow, P.; Obert, H. J. und Zipp, F. (2003): Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients, J Neuroimmunol 137) [1-2], Seite 187-96.

Goebels, N.; Hofstetter, H.; Schmidt, S.; Brunner, C.; Wekerle, H. und Hohlfeld, R. (2000): Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence, Brain 123 Pt 3), Seite 508-18.

Gong, B. und Almasan, A. (2000): Genomic organization and transcriptional regulation of human Apo2/ TRAIL gene, Biochem Biophys Res Commun 278) [3], Seite 747-52.

Greaves, M.; Janossy, G. und Doenhoff, M. (1974): Selective triggering of human T and B lymphocytes in vitro by polyclonal mitogens, J Exp Med 140) [1], Seite 1-18..

Griffith, T. S.; Wiley, S. R.; Kubin, M. Z.; Sedger, L. M.; Maliszewski, C. R. und Fanger, N. A. (1999): Monocyte-mediated tumoricidal activity via the tumor necrosis factor- related cytokine, TRAIL, J Exp Med 189) [8], Seite 1343-54..

Haines, J. L.; Terwedow, H. A.; Burgess, K.; Pericak-Vance, M. A.; Rimmler, J. B.; Martin, E. R.; Oksenberg, J. R.; Lincoln, R.; Zhang, D. Y.; Banatao, D. R.; Gatto, N.; Goodkin, D. E. und Hauser, S. L. (1998): Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group, Hum Mol Genet 7) [8], Seite 1229-34.

Halaas, O.; Vik, R.; Ashkenazi, A. und Espevik, T. (2000): Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages, Scand J Immunol 51) [3], Seite 244-50..

Hartung, H. P.; Gonsette, R.; Konig, N.; Kwiecinski, H.; Guseo, A.; Morrissey, S. P.; Krapf, H. und Zwingers, T. (2002): Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet 360) [9350], Seite 2018-25.

Hill, J. A.; Polgar, K. und Anderson, D. J. (1995): T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion, Jama 273) [24], Seite 1933-6.

Hillert, J. und Masterman, T. (2001): The genetics of multiple sclerosis, Cook, S.D., Handbook of multiplesclerosis. 3rd ed., Seite 33-65, Marcel Dekker, New York.

Hilliard, B.; Wilmen, A.; Seidel, C.; Liu, T. S.; Goke, R. und Chen, Y. (2001): Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis, J Immunol 166) [2], Seite 1314-9..

Huang, W. X.; Huang, M. P.; Gomes, M. A. und Hillert, J. (2000): Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS, Neurology 55) [7], Seite 928-34..

Inoue, A.; Koh, C. S.; Sakai, T.; Yamazaki, M.; Yanagisawa, N.; Usuku, K. und Osame, M. (1997): Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy, J Neuroimmunol 75) [1-2], Seite 141-6.

Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J. L.; Schroter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; French, L. E. und Tschopp, J. (1997): Inhibition of death receptor signals by cellular FLIP, Nature 388) [6638], Seite 190-5.

Itoh, N.; Yonehara, S.; Ishii, A.; Yonehara, M.; Mizushima, S.; Sameshima, M.; Hase, A.; Seto, Y. und Nagata, S. (1991): The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis, Cell 66) [2], Seite 233-43.

Jacobs, L. D.; Beck, R. W.; Simon, J. H.; Kinkel, R. P.; Brownscheidle, C. M.; Murray, T. J.; Simonian, N. A.; Slasor, P. J. und Sandrock, A. W. (2000): Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group, N Engl J Med 343) [13], Seite 898-904.

Janeway, C.A.; Travers, P.; Walport, M. und Capra, J.D. (1999): Immunobiology: the immune system in health and disease, Janeway, C., Elsevier Science Ltd/Garland Publishing, London.

Jenkinson, E. J.; Kingston, R.; Smith, C. A.; Williams, G. T. und Owen, J. J. (1989): Antigen-induced apoptosis in developing T cells: a mechanism for negative selection of the T cell receptor repertoire, Eur J Immunol 19) [11], Seite 2175-7.

Jeppson, J. D.; Patel, H. R.; Sakata, N.; Domenico, J.; Terada, N. und Gelfand, E. W. (1998): Requirement for dual signals by anti-CD40 and IL-4 for the induction of nuclear factor-kappa B, IL-6, and IgE in human B lymphocytes, J Immunol 161) [4], Seite 1738-42..

Jiang, J. D.; Schlesinger, M.; Sacks, H.; Mildvan, D.; Roboz, J. P. und Bekesi, J. G. (1997): Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status, J Clin Immunol 17) [2], Seite 185-92.

Jo, M.; Kim, T. H.; Seol, D. W.; Esplen, J. E.; Dorko, K.; Billiar, T. R. und Strom, S. C. (2000): Apoptosis induced in normal human hepatocytes by tumor necrosis factor- related apoptosis-inducing ligand, Nat Med 6) [5], Seite 564-7..

Johnson, K. P.; Brooks, B. R.; Cohen, J. A.; Ford, C. C.; Goldstein, J.; Lisak, R. P.; Myers, L. W.; Panitch, H. S.; Rose, J. W. und Schiffer, R. B. (1995): Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology 45) [7], Seite 1268-76.

Johnson, K. P.; Brooks, B. R.; Cohen, J. A.; Ford, C. C.; Goldstein, J.; Lisak, R. P.; Myers, L. W.; Panitch, H. S.; Rose, J. W.; Schiffer, R. B.; Vollmer, T.; Weiner, L. P. und Wolinsky, J. S. (1998): Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group, Neurology 50) [3], Seite 701-8.

Kaser, A.; Deisenhammer, F.; Berger, T. und Tilg, H. (1999): Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients, Lancet 353) [9162], Seite 1413-4.

Kastrukoff, L.F. und Rice, G.P.A. (1997): Virology, Paty, D. W. und Ebers, G. C., Multiple sclerosis, Seite 370-402, FA Davis, Philadelphia.

Kayagaki, N.; Yamaguchi, N.; Nakayama, M.; Eto, H.; Okumura, K. und Yagita, H. (1999): Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs, J Exp Med 189) [9], Seite 1451-60..

Kerr, J. F.; Winterford, C. M. und Harmon, B. V. (1994): Apoptosis. Its significance in cancer and cancer therapy, Cancer 73) [8], Seite 2013-26.

Kerr, J. F.; Wyllie, A. H. und Currie, A. R. (1972): Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Br J Cancer 26) [4], Seite 239-57.

Khan, O. A. und Dhib-Jalbut, S. S. (1998): Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients, Neurology 51) [3], Seite 738-42..

Kieseier, B. C. und Hartung, H. P. (2003): Current disease-modifying therapies in multiple sclerosis, Semin Neurol 23) [2], Seite 133-46.

Kimura, M.; Tomita, Y.; Imai, T.; Saito, T.; Katagiri, A.; Tanikawa, T.; Takeda, M. und Takahashi, K. (1999): Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients, Br J Cancer 80) [10], Seite 1648-51.

Klas, C.; Debatin, K. M.; Jonker, R. R. und Krammer, P. H. (1993): Activation interferes with the APO-1 pathway in mature human T cells, Int Immunol 5) [6], Seite 625-30.

Knipping, E.; Debatin, K. M.; Stricker, K.; Heilig, B.; Eder, A. und Krammer, P. H. (1995): Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias, Blood 85) [6], Seite 1562-9.

Kovacs, B.; Szentendrei, T.; Bednarek, J. M.; Pierson, M. C.; Mountz, J. D.; Vogelgesang, S. A. und Tsokos, G. C. (1997): Persistent expression of a soluble form of Fas/APO1 in continuously activated T cells from a patient with SLE, Clin Exp Rheumatol 15) [1], Seite 19-23.

Krammer, P. H. (1999): CD95(APO-1/Fas)-mediated apoptosis: live and let die, Adv Immunol 71), Seite 163-210.

Krueger, A.; Fas, S. C.; Baumann, S. und Krammer, P. H. (2003): The role of CD95 in the regulation of peripheral T-cell apoptosis, Immunol Rev 193), Seite 58-69.

Kumar-Sinha, C.; Varambally, S.; Sreekumar, A. und Chinnaiyan, A. M. (2002): Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways, J Biol Chem 277) [1], Seite 575-85..

Kurtzke, J.F. (1983): Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology 33) [11], Seite 1444-52.

Langstein, J.; Becke, F. M.; Sollner, L.; Krause, G.; Brockhoff, G.; Kreutz, M.; Andreesen, R. und Schwarz, H. (2000): Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation, Biochem Biophys Res Commun 273) [1], Seite 117-22..

Leithauser, F.; Dhein, J.; Mechtersheimer, G.; Koretz, K.; Bruderlein, S.; Henne, C.; Schmidt, A.; Debatin, K. M.; Krammer, P. H. und Moller, P. (1993): Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells, Lab Invest 69) [4], Seite 415-29.

Lenardo, M.; Chan, K. M.; Hornung, F.; McFarland, H.; Siegel, R.; Wang, J. und Zheng, L. (1999): Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment, Annu Rev Immunol 17), Seite 221-53.

Lewis, R. S. und Cahalan, M. D. (1995): Potassium and calcium channels in lymphocytes, Annu Rev Immunol 13), Seite 623-53.

Li-Weber, M. und Krammer, P. H. (2003): Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system, Semin Immunol 15) [3], Seite 145-57.

Li, L.; Krajewski, S.; Reed, J. C. und Choi, Y. S. (1997): The apoptosis and proliferation of SAC-activated B cells by IL-10 are associated with changes in Bcl-2, Bcl-xL, and Mcl-1 expression, Cell Immunol 178) [1], Seite 33-41.

Liu, C.; Cheng, J. und Mountz, J. D. (1995): Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation, Biochem J 310 ( Pt 3)), Seite 957-63.

Liu, J. H.; Wei, S.; Lamy, T.; Li, Y.; Epling-Burnette, P. K.; Djeu, J. Y. und Loughran, T. P., Jr. (2002): Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia, Blood 100) [4], Seite 1449-53.

Loo, D. T. und Rillema, J. R. (1998): Measurement of cell death, Methods Cell Biol 57), Seite 251-64.

Lublin, F. D. und Reingold, S. C. (1996): Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology 46) [4], Seite 907-11.

Lucchinetti, C. F.; Brueck, W.; Rodriguez, M. und Lassmann, H. (1998): Multiple sclerosis: lessons from neuropathology, Semin Neurol 18) [3], Seite 337-49.

Lunemann, J. D.; Waiczies, S.; Ehrlich, S.; Wendling, U.; Seeger, B.; Kamradt, T. und Zipp, F. (2002): Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells, J Immunol 168) [10], Seite 4881-8.

Macchi, B.; Matteucci, C.; Nocentini, U.; Caltagirone, C. und Mastino, A. (1999): Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis, Neuroreport 10) [2], Seite 399-402..

MacEwan, D. J. (2002): TNF receptor subtype signalling: differences and cellular consequences, Cell Signal 14) [6], Seite 477-92.

MacFarlane, M.; Cohen, G. M. und Dickens, M. (2000): JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation, Biochem J 348 Pt 1), Seite 93-101.

Mariani, S. M. und Krammer, P. H. (1998): Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage, Eur J Immunol 28) [3], Seite 973-82..

Markovic-Plese, S. und McFarland, H. F. (2001): Immunopathogenesis of the multiple sclerosis lesion, Curr Neurol Neurosci Rep 1) [3], Seite 257-62.

Martin, R. und McFarland, H. F. (1995): Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis, Crit Rev Clin Lab Sci 32) [2], Seite 121-82.

Martinez Lorenzo, M. J.; Alava, M. A.; Gamen, S.; Kim, K. J.; Chuntharapai, A.; Pineiro, A.; Naval, J. und Anel, A. (1998): Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells, Eur J Immunol 28) [9], Seite 2714-25.

Martinez Lorenzo, M. J.; Anel, A.; Gamen, S.; Monle n, I.; Lasierra, P.; Larrad, L.; Pineiro, A.; Alava, M. A. und Naval, J. (1999): Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles, J Immunol 163) [3], Seite 1274-81.

McDonald, W. I.; Compston, A.; Edan, G.; Goodkin, D.; Hartung, H. P.; Lublin, F. D.; McFarland, H. F.; Paty, D. W.; Polman, C. H.; Reingold, S. C.; Sandberg-Wollheim, M.; Sibley, W.; Thompson, A.; van den Noort, S.; Weinshenker, B. Y. und Wolinsky, J. S. (2001): Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol 50) [1], Seite 121-7.

Melino, G. (2001): The Sirens' song, Nature 412) [6842], Seite 23.

Monleon, I.; Martinez Lorenzo, M. J.; Anel, A.; Lasierra, P.; Larrad, L.; Pineiro, A.; Naval, J. und Alava, M. A. (2000): CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells, Eur J Immunol 30) [4], Seite 1078-87.

Nagata, S. (1997): Apoptosis by death factor, Cell 88) [3], Seite 355-65.

Nagata, S. (1998): Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model, J Hum Genet 43) [1], Seite 2-8.

Nagata, S. und Golstein, P. (1995): The Fas death factor, Science 267) [5203], Seite 1449-56.

Nagata, S. und Suda, T. (1995): Fas and Fas ligand: lpr and gld mutations, Immunol Today 16) [1], Seite 39-43.

Neuhaus, O.; Kieseier, B. C. und Hartung, H. P. (2004): Mechanisms of mitoxantrone in multiple sclerosis-what is known?, J Neurol Sci 223) [1], Seite 25-7.

Nicoletti, I.; Migliorati, G.; Pagliacci, M.C. ; Grignani, F. und Riccardi, C. (1991): A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry, J Immunol Methods 139) [2], Seite 271-9.

Nitsch, R.; Bechmann, I.; Deisz, R. A.; Haas, D.; Lehmann, T. N.; Wendling, U. und Zipp, F. (2000): Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL), Lancet 356) [9232], Seite 827-8..

Noseworthy, J. H. (2003): Management of multiple sclerosis: current trials and future options, Curr Opin Neurol 16) [3], Seite 289-97.

O'Riordan, J. I.; Thompson, A. J.; Kingsley, D. P.; MacManus, D. G.; Kendall, B. E.; Rudge, P.; McDonald, W. I. und Miller, D. H. (1998): The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up, Brain 121 ( Pt 3)), Seite 495-503.

Oritani, K.; Kincade, P. W.; Zhang, C.; Tomiyama, Y. und Matsuzawa, Y. (2001): Type I interferons and limitin: a comparison of structures, receptors, and functions, Cytokine Growth Factor Rev 12) [4], Seite 337-48..

Pan, G.; Ni, J.; Wei, Y. F.; Yu, G.; Gentz, R. und Dixit, V. M. (1997): An antagonist decoy receptor and a death domain-containing receptor for TRAIL, Science 277) [5327], Seite 815-8..

Papoff, G.; Cascino, I.; Eramo, A.; Starace, G.; Lynch, D. H. und Ruberti, G. (1996): An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro, J Immunol 156) [12], Seite 4622-30.

Pette, M.; Pette, D. F.; Muraro, P. A.; Farnon, E.; Martin, R. und McFarland, H. F. (1997): Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes, Neurology 49) [2], Seite 385-92..

Pilling, D.; Akbar, A. N.; Girdlestone, J.; Orteu, C. H.; Borthwick, N. J.; Amft, N.; Scheel-Toellner, D.; Buckley, C. D. und Salmon, M. (1999): Interferon-beta mediates stromal cell rescue of T cells from apoptosis, Eur J Immunol 29) [3], Seite 1041-50.

Pitti, R. M.; Marsters, S. A.; Lawrence, D. A.; Roy, M.; Kischkel, F. C.; Dowd, P.; Huang, A.; Donahue, C. J.; Sherwood, S. W.; Baldwin, D. T.; Godowski, P. J.; Wood, W. I.; Gurney, A. L.; Hillan, K. J.; Cohen, R. L.; Goddard, A. D.; Botstein, D. und Ashkenazi, A. (1998): Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer, Nature 396) [6712], Seite 699-703.

Pitti, R. M.; Marsters, S. A.; Ruppert, S.; Donahue, C. J.; Moore, A. und Ashkenazi, A. (1996): Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family, J Biol Chem 271) [22], Seite 12687-90..

Podack, E. R. (1995): Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways, Curr Opin Immunol 7) [1], Seite 11-6..

Poser, C. M.; Paty, D. W.; Scheinberg, L.; McDonald, W. I.; Davis, F. A.; Ebers, G. C.; Johnson, K. P.; Sibley, W. A.; Silberberg, D. H. und Tourtellotte, W. W. (1983): New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol 13) [3], Seite 227-31.

Pryse-Phillips, W. und Costello, F. (2001): The epidemiology of multiple sclerosis., Cook, S.D., Handbook of multiplesclerosis. 3rd ed., Seite 15-31, Marcel Dekker, New York.

Qian, D. und Weiss, A. (1997): T cell antigen receptor signal transduction, Curr Opin Cell Biol 9) [2], Seite 205-12.

Rabehi, L.; Irinopoulou, T.; Cholley, B.; Haeffner-Cavaillon, N. und Carreno, M. P. (2001): Gram-positive and gram-negative bacteria do not trigger monocytic cytokine production through similar intracellular pathways, Infect Immun 69) [7], Seite 4590-9.

Rep, M. H.; Schrijver, H. M.; van Lopik, T.; Hintzen, R. Q.; Roos, M. T.; Ader, H. J.; Polman, C. H. und van Lier, R. A. (1999): Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients, J Neuroimmunol 96) [1], Seite 92-100.

Rieux-Laucat, F.; Le Deist, F.; Hivroz, C.; Roberts, I. A.; Debatin, K. M.; Fischer, A. und de Villartay, J. P. (1995): Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity, Science 268) [5215], Seite 1347-9.

Roth, W.; Isenmann, S.; Naumann, U.; Kugler, S.; Bahr, M.; Dichgans, J.; Ashkenazi, A. und Weller, M. (1999): Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity, Biochem Biophys Res Commun 265) [2], Seite 479-83.

Sabelko-Downes, K. A.; Cross, A. H. und Russell, J. H. (1999): Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis, J Exp Med 189) [8], Seite 1195-205.

Sakaguchi, S. (2000): Regulatory T cells: key controllers of immunologic self-tolerance, Cell 101) [5], Seite 455-8.

Sakai, T.; Inoue, A.; Koh, C. S. und Osame, M. (1999): Serum levels of apoptosis-related molecules in patients with multiple sclerosis and human T-lymphotropic virus Type I-associated myelopathy, J Interferon Cytokine Res 19) [9], Seite 999-1004.

Santiago, B.; Galindo, M.; Palao, G. und Pablos, J. L. (2004): Intracellular regulation of Fas-induced apoptosis in human fibroblasts by extracellular factors and cycloheximide, J Immunol 172) [1], Seite 560-6.

Schmidt, R.M. und Hoffmann, Frank (2002): Multiple Sklerose. Epidemiologie, Diagnostik, Therapie., 3. neubearbeitete und erweiterte Auflage. Auflage, Urban & Fischer, München.

Schmied, M.; Breitschopf, H.; Gold, R.; Zischler, H.; Rothe, G.; Wekerle, H. und Lassmann, H. (1993): Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain, Am J Pathol 143) [2], Seite 446-52.

Sega, S.; Wraber, B. ; Mesec, A. ; Horvat, A. und Ihan, A. (2004): IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines, Clin Neurol Neurosurg 106) [3], Seite 255-8.

Sheridan, J. P.; Marsters, S. A.; Pitti, R. M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C. L.; Baker, K.; Wood, W. I.; Goddard, A. D.; Godowski, P. und Ashkenazi, A. (1997): Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors, Science 277) [5327], Seite 818-21..

Sicotte, N. L.; Liva, S. M.; Klutch, R.; Pfeiffer, P.; Bouvier, S.; Odesa, S.; Wu, T. C. und Voskuhl, R. R. (2002): Treatment of multiple sclerosis with the pregnancy hormone estriol, Ann Neurol 52) [4], Seite 421-8.

Singer, J.D. und Willett, J.B. (2003): Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence., Oxford Press, New York.

Smith, K. A.; Gillis, S.; Baker, P. E.; McKenzie, D. und Ruscetti, F. W. (1979): T-cell growth factor-mediated T-cell proliferation, Ann N Y Acad Sci 332), Seite 423-32.

Snell, V.; Clodi, K.; Zhao, S.; Goodwin, R.; Thomas, E. K.; Morris, S. W.; Kadin, M. E.; Cabanillas, F.; Andreeff, M. und Younes, A. (1997): Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies, Br J Haematol 99) [3], Seite 618-24..

Soldan, S. S.; Alvarez Retuerto, A. I.; Sicotte, N. L. und Voskuhl, R. R. (2003): Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol, J Immunol 171) [11], Seite 6267-74.

Sommer, N.; Zipp, F.; Rosener, M.; Dichgans, J. und Martin, R. (1996): [Influence of genetic factors on multiple sclerosis], Nervenarzt 67) [6], Seite 457-64.

Song, K.; Chen, Y.; Goke, R.; Wilmen, A.; Seidel, C.; Goke, A. und Hilliard, B. (2000): Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression, J Exp Med 191) [7], Seite 1095-104..

Sorensen, P. S.; Fazekas, F. und Lee, M. (2002): Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis, Eur J Neurol 9) [6], Seite 557-63.

Stark, G. R.; Kerr, I. M.; Williams, B. R.; Silverman, R. H. und Schreiber, R. D. (1998): How cells respond to interferons, Annu Rev Biochem 67), Seite 227-64.

Strasser, A.; O'Connor, L. und Dixit, V. M. (2000): Apoptosis signaling, Annu Rev Biochem 69), Seite 217-45.

Suda, T.; Takahashi, T.; Golstein, P. und Nagata, S. (1993): Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family, Cell 75) [6], Seite 1169-78.

Trapp, B. D.; Peterson, J.; Ransohoff, R. M.; Rudick, R.; Mork, S. und Bo, L. (1998): Axonal transection in the lesions of multiple sclerosis, N Engl J Med 338) [5], Seite 278-85.

Trapp, B. D.; Ransohoff, R. und Rudick, R. (1999): Axonal pathology in multiple sclerosis: relationship to neurologic disability, Curr Opin Neurol 12) [3], Seite 295-302.

Trauth, B. C.; Klas, C.; Peters, A. M.; Matzku, S.; Moller, P.; Falk, W.; Debatin, K. M. und Krammer, P. H. (1989): Monoclonal antibody-mediated tumor regression by induction of apoptosis, Science 245) [4915], Seite 301-5.

Trump, B. F.; Berezesky, I. K.; Chang, S. H. und Phelps, P. C. (1997): The pathways of cell death: oncosis, apoptosis, and necrosis, Toxicol Pathol 25) [1], Seite 82-8.

Vidalain, P. O.; Azocar, O.; Yagita, H.; Rabourdin-Combe, C. und Servet-Delprat, C. (2001): Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand, J Immunol 167) [7], Seite 3765-72..

Viglietta, V.; Baecher-Allan, C.; Weiner, H. L. und Hafler, D. A. (2004): Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis, J Exp Med 199) [7], Seite 971-9.

Vukusic, S. und Confavreux, C. (2001): The natural history of multiple sclerosis., Cook, S.D., Handbook of multiple sclerosis. 3rd ed., Seite 433-477, Marcel Dekker, New York.

Waiczies, S.; Weber, A.; Lunemann, J. D.; Aktas, O.; Zschenderlein, R. und Zipp, F. (2002): Elevated Bcl-X(L) levels correlate with T cell survival in multiple sclerosis, J Neuroimmunol 126) [1-2], Seite 213-20.

Walczak, H.; Bouchon, A.; Stahl, H. und Krammer, P. H. (2000): Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells, Cancer Res 60) [11], Seite 3051-7.

Walczak, H. und Krammer, P. H. (2000): The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems, Exp Cell Res 256) [1], Seite 58-66.

Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh, J.C., Lynch, D.H. (1999): Tumoridical activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo., Nat Med 5) [2], Seite 157-63.

Wandinger, K. P.; Lunemann, J. D.; Wengert, O.; Bellmann-Strobl, J.; Aktas, O.; Weber, A.; Grundstrom, E.; Ehrlich, S.; Wernecke, K. D.; Volk, H. D. und Zipp, F. (2003): TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis, Lancet 361) [9374], Seite 2036-43.

Wandinger, K. P.; Sturzebecher, C. S.; Bielekova, B.; Detore, G.; Rosenwald, A.; Staudt, L. M.; McFarland, H. F. und Martin, R. (2001): Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes, Ann Neurol 50) [3], Seite 349-57..

Wang, J.; Taniuchi, I.; Maekawa, Y.; Howard, M.; Cooper, M. D. und Watanabe, T. (1996): Expression and function of Fas antigen on activated murine B cells, Eur J Immunol 26) [1], Seite 92-6.

Wang, X.; Chen, M.; Wandinger, K. P.; Williams, G. und Dhib-Jalbut, S. (2000): IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis, J Immunol 165) [1], Seite 548-57.

Watanabe, D.; Suda, T. und Nagata, S. (1995): Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells, Int Immunol 7) [12], Seite 1949-56.

Weber, A.; Wandinger, K. P.; Mueller, W.; Aktas, O.; Wengert, O.; Grundstrom, E.; Ehrlich, S.; Windemuth, C.; Kuhlmann, T.; Wienker, T.; Bruck, W. und Zipp, F. (2004): Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis, J Neuroimmunol 149) [1-2], Seite 195-201.

Weber, F.; Janovskaja, J.; Polak, T.; Poser, S. und Rieckmann, P. (1999): Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b, Neurology 52) [5], Seite 1069-71.

Weinshenker, B. G. und Ebers, G. C. (1987): The natural history of multiple sclerosis, Can J Neurol Sci 14) [3], Seite 255-61.

Wekerle, H. (1993): T-cell autoimmunity in the central nervous system, Intervirology 35) [1-4], Seite 95-100.

Wendling, U.; Walczak, H.; Dorr, J.; Jaboci, C.; Weller, M.; Krammer, P. H. und Zipp, F. (2000): Expression of TRAIL receptors in human autoreactive and foreign antigen- specific T cells, Cell Death Differ 7) [7], Seite 637-44..

Whitaker, J. N. und Mitchell, G. W. (1996): A possible role for altered myelin basic protein in multiple sclerosis, Ann Neurol 40) [1], Seite 3-4.

Wucherpfennig, K. W. (2001): Mechanisms for the induction of autoimmunity by infectious agents, J Clin Invest 108) [8], Seite 1097-104.

Wucherpfennig, K. W. und Strominger, J. L. (1995): Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein, Cell 80) [5], Seite 695-705.

Yong, V. W.; Chabot, S.; Stuve, O. und Williams, G. (1998): Interferon beta in the treatment of multiple sclerosis: mechanisms of action, Neurology 51) [3], Seite 682-9.

Young, T. H.; Lin, D. T. und Chen, L. Y. (2000): Human monocyte adhesion and activation on crystalline polymers with different morphology and wettability in vitro, J Biomed Mater Res 50) [4], Seite 490-8.

Yue, T. L.; Wang, X.; Louden, C. S.; Gupta, S.; Pillarisetti, K.; Gu, J. L.; Hart, T. K.; Lysko, P. G. und Feuerstein, G. Z. (1997): 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression, Mol Pharmacol 51) [6], Seite 951-62.

Zamai, L.; Secchiero, P.; Pierpaoli, S.; Bassini, A.; Papa, S.; Alnemri, E. S.; Guidotti, L.; Vitale, M. und Zauli, G. (2000): TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis, Blood 95) [12], Seite 3716-24.

Zang, Y. C.; Kozovska, M. M.; Hong, J.; Li, S.; Mann, S.; Killian, J. M.; Rivera, V. M. und Zhang, J. Z. (1999): Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis, Eur J Immunol 29) [5], Seite 1692-700..

Zhang, J. und Raus, J. (1994): Myelin basic protein-reactive T cells in multiple sclerosis: pathologic relevance and therapeutic targeting, Cytotechnology 16) [3], Seite 181-7.

Zhao, S.; Asgary, Z.; Wang, Y.; Goodwin, R.; Andreeff, M. und Younes, A. (1999): Functional expression of TRAIL by lymphoid and myeloid tumour cells, Br J Haematol 106) [3], Seite 827-32..

Zipp, F. (2000): Apoptosis in multiple sclerosis, Cell Tissue Res 301) [1], Seite 163-71.

Zipp, F.; Beyer, M.; Gelderblom, H.; Wernet, D.; Zschenderlein, R. und Weller, M. (2000): No induction of apoptosis by IFN-beta in human antigen-specific T cells, Neurology 54) [2], Seite 485-7..

Zipp, F.; Faber, E.; Sommer, N.; Muller, C.; Dichgans, J.; Krammer, P. H.; Martin, R. und Weller, M. (1998): CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2, J Neuroimmunol 81) [1-2], Seite 168-72.

Zipp, F.; Kerschensteiner, M.; Dornmair, K.; Malotka, J.; Schmidt, S.; Bender, A.; Giegerich, G.; de Waal Malefyt, R.; Wekerle, H. und Hohlfeld, R. (1998): Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis, Brain 121 ( Pt 8)), Seite 1395-407.

Zipp, F.; Krammer, P. H. und Weller, M. (1999): Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system, Immunol Today 20) [12], Seite 550-4. 00001545 00001545.

Zipp, F.; Martin, R.; Lichtenfels, R.; Roth, W.; Dichgans, J.; Krammer, P. H. und Weller, M. (1997): Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand, J Immunol 159) [5], Seite 2108-15..

Zipp, F.; Otzelberger, K.; Dichgans, J.; Martin, R. und Weller, M. (1998): Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis, J Neuroimmunol 86) [2], Seite 151-4..

Zipp, F.; Sommer, N.; Rosener, M.; Dichgans, J. und Martin, R. (1997): [Multiple sclerosis. New therapeutic strategies in the experimental stage], Nervenarzt 68) [2], Seite 94-101.

Zipp, F.; Weil, J. G. und Einhaupl, K. M. (1999): No increase in demyelinating diseases after hepatitis B vaccination, Nat Med 5) [9], Seite 964-5.

Zipp, F.; Weller, M.; Calabresi, P. A.; Frank, J. A.; Bash, C. N.; Dichgans, J.; McFarland, H. F. und Martin, R. (1998): Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis, Ann Neurol 43) [1], Seite 116-20.

Zipp, F.; Wendling, U.; Beyer, M.; Grieger, U.; Waiczies, S.; Wagenknecht, B.; Haas, J. und Weller, M. (2000): Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells, J Neuroimmunol 110) [1-2], Seite 214-22.

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: